Anti-TNFβ/LTA Antibody, clone 3B20-H2 ZooMAb® Rabbit Monoclonal

newenhanced validation

recombinant, expressed in HEK 293 cells

Quality Level

biological source



expressed in HEK 293 cells

antibody form

purified antibody

antibody product type

primary antibodies


3B20-H2, recombinant monoclonal


recombinant, expressed in HEK 293 cells

product line

ZooMAb® learn more



mol wt

calculated mol wt 22.30 kDa
observed mol wt ~17 kDa

species reactivity


species reactivity (predicted by homology)



antibody small pack of 25 μL

enhanced validation

recombinant expression
Learn more about Antibody Enhanced Validation


flow cytometry: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: suitable



epitope sequence

N-terminal half



Protein ID accession no.

UniProt accession no.

shipped in


storage temp.


General description

ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.


Clone 3B20-H2 is a ZooMAb® rabbit recombinant monoclonal antibody that specifically detects TNFβ/LTA.


KLH-conjugated linear peptide corresponding to 20 amino acids from the N-terminal half of human TNFβ (Lymphotoxin-a).


Anti-TNFβ/LTA, clone 3B20-H2 ZooMAb®, Cat. No. ZRB1195, is Rabbit monoclonal antibody that specifically targets TNFβ/LTA and is tested for use in Flow Cytometry, Immunohistochemistry (Paraffin), and Western Blotting.
Quality Control Testing

Evaluated by Western Blotting with human recombinant TNFβ/LTA.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected recombinant human TNFβ/LTA.

Tested applications

Flow Cytometry Analysis: 1 mg from a representative lot detected TNFβ/LTA in one million HepG2 cells.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected TNFβ/LTA in human tonsil tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Target description

Lymphotoxin-a (UniProt: P01374; also known as LT-alpha, TNF-beta, Tumor necrosis factor ligand superfamily member 1) is encoded by the LTA (also known as TNFB, TNFSF1) gene (Gene ID: 4049) in human. Lymphotoxin-a is cytokine of the tumor necrosis family that is synthesized by lymphocytes with a signal peptide (aa 1-34), which is subsequently cleaved off to generate the mature form. It is shown to be cytotoxic for a wide range of tumor cells in vitro and in vivo. It can exist as a secreted homotrimeric form or can form a heterotrimer with lymphotoxin-a to become a membrane associated form. The homotrimeric form is shown to bind to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM and the heterotrimer binds exclusively to TNFRSF3/Lymphotoxin- receptor (LTBR). Lymphotoxin- is reported to be involved in the formation of secondary lymphoid organs during development and play a role in apoptosis. Mutations in LTA gene are known to cause Psoriatic arthritis, an inflammatory seronegative arthritis, which is a heterogeneous disorder that can range from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.


300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany


Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.